Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.43, Iss.4, 2004-01, pp. : 267-278

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of CYP2C9 polymorphisms on pharmacokinetics of nateglinide

Inpharma, Vol. 1, Iss. 1429, 2004-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects

By Sabia Helene Sunkara Gangadhar Ligueros-Saylan Monica Wang Yibin Smith Harold McLeod James Prasad Pratapa

European Journal of Clinical Pharmacology, Vol. 60, Iss. 6, 2004-09 ,pp. : 407-412

Springer Publishing Company

Access to resources Recommend Favorite

Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers

By Gassó Patricia Papagianni Katerina Mas Sergi de Bobadilla Ramón Fernández Arnaiz Joan Albert Bernardo Miquel Lafuente Amalia

Pharmacogenomics, Vol. 14, Iss. 13, 2013-10 ,pp. : 1551-1563

Future Medicine

Access to resources Recommend Favorite

CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers

By LLerena Adrian Dorado Pedro Ramírez Ronald Calzadilla Luis R Peñas-LLedó Eva Álvarez Mayra Naranjo María EG González Idilio Pérez Bárbaro

Pharmacogenomics, Vol. 14, Iss. 16, 2013-12 ,pp. : 1973-1977

Future Medicine

Access to resources Recommend Favorite

Pharmacogenetic Prediction of Individual Variability in Drug Response Based on CYP2D6, CYP2C9 and CYP2C19 Genetic Polymorphisms

Current Drug Metabolism, Vol. 15, Iss. 7, 2014-09 ,pp. : 711-718

Bentham Science Publishers

Access to resources Recommend Favorite